|
WO2021060341A1
|
|
Use of dnmt inhibitor
|
|
WO2020090698A1
|
|
Pharmaceutical composition
|
|
WO2020183688A1
|
|
Disease diagnosis/treatment assistance system
|
|
WO2019160127A1
|
|
Use of dnmt inhibitor
|
|
WO2019146642A1
|
|
METHOD FOR IMPROVING CHEMICAL STABILITY OF γ-AMINOBUTYRIC ACID DERIVATIVE- CONTAINING TABLET
|
|
WO2019124358A1
|
|
Method for improving chemical stability of pregabalin by particle size control
|
|
WO2019111960A1
|
|
Amorphous-solifenacin drug package
|
|
WO2019098327A1
|
|
Orally disintegrating tablet having suppressed bitterness of fast dissolving drug
|
|
WO2018230479A1
|
|
5'-position silyl ether derivative for nucleoside anti-cancer agent or anti-virus agent
|
|
CN110678473A
|
|
5' -dibenzyl monophosphate derivatives of nucleoside anticancer or antiviral drugs
|
|
WO2018199049A1
|
|
Novel dnmt inhibitor as solid tumor therapeutic drug
|
|
US2018179246A1
|
|
Silyl etherified derivatives of 5-azacytidines in carbohydrate moiety
|
|
US2017304337A1
|
|
Silyl etherified derivatives of 5-azacytidines in carbohydrate moiety
|
|
WO2017183215A1
|
|
Sugar moiety silyl ether derivative of 5-azacytidine
|
|
WO2017090264A1
|
|
5'-position dibenzyl phosphoric acid ester of 5-azacytidine or 2'-deoxy body thereof
|
|
WO2016114017A1
|
|
Film-coated tablets containing olmesartan medoxomil
|
|
CA2704826A1
|
|
Method for producing granulated preparation
|
